crobenetine
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 1999 (NCT02268136)
Timeline
Indications
Studied for
Mechanism of action
SCN9A inhibitor
SCN10A inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C[C@@H](CN1CC[C@H]2c3ccccc3C[C@@H]1C2(C)C)OCc4ccccc4- Mol. weight
- 349.52 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3039733 ↗
- ChEMBLCHEMBL2104084 ↗
Also known as
- 1,2,3,4,5,6-hexahydro-6,11,11-trimethyl-3-(2-(phenylmethoxy)propyl)-2,6-methano-3-benzazocin-10-ol
- biii 890 cl
- biii 890 cl
- biii 890 cl
- biii-890-cl
- crobenetine
- crobenetine
- crobenetine
- crobenetine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02269202 | Phase 1 | Feb 1, 2002 | Boehringer Ingelheim |
| NCT02273466 | Phase 1 | Feb 1, 2002 | Boehringer Ingelheim |
| NCT02251197 | Phase 2 | Jul 1, 2001 | Boehringer Ingelheim |
| NCT02269215 | Phase 1 | Jan 1, 2000 | Boehringer Ingelheim |
| NCT02268136 | Phase 1 | Apr 1, 1999 | Boehringer Ingelheim |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 5 | 5 | 2 | 1999 |
1 organizations
Page 1 / 1